Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Lymphoma

  Free Subscription

Articles published in Eur J Haematol

Retrieve available abstracts of 91 articles:
HTML format

Single Articles

    July 2021
  1. METZNER B, Pott C, Muller TH, Casper J, et al
    Long-term outcome in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation.
    Eur J Haematol. 2021 Jul 20. doi: 10.1111/ejh.13691.
    PubMed     Abstract available

  2. WIGHT J, Wai SH, Shen E, Lee ST, et al
    Predicting primary treatment failure using interim FDG-PET scanning in Diffuse large B-cell lymphoma.
    Eur J Haematol. 2021 Jul 8. doi: 10.1111/ejh.13684.
    PubMed     Abstract available

  3. WU X, Nowakowski KE, Abeykoon JP, Manske M, et al
    MCIR1: A Patient-Derived Mantle Cell Lymphoma Line for Discovering New Treatments for Ibrutinib Resistance.
    Eur J Haematol. 2021 Jul 2. doi: 10.1111/ejh.13682.
    PubMed     Abstract available

    May 2021
  4. RENAUD L, Bossard JB, Carpentier B, Terriou L, et al
    Treatment with temozolomide and ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL).
    Eur J Haematol. 2021 May 21. doi: 10.1111/ejh.13667.
    PubMed     Abstract available

  5. SHANMUGASUNDARAM K, Goyal S, Switchenko J, Calzada O, et al
    Intensive Induction Regimens after Deferring Initial Therapy for Mantle Cell Lymphoma Are Not Associated with Improved Survival.
    Eur J Haematol. 2021 May 11. doi: 10.1111/ejh.13649.
    PubMed     Abstract available

  6. SIEG N, Naendrup JH, Godel P, Balke-Want H, et al
    Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma - feasibility of MTX-based regimens in clinical routine.
    Eur J Haematol. 2021 May 7. doi: 10.1111/ejh.13639.
    PubMed     Abstract available

  7. HANSEN S, Alduaij W, Biggs CM, Belga S, et al
    Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
    Eur J Haematol. 2021;106:654-661.
    PubMed     Abstract available

    April 2021
  8. YUDA S, Maeshima AM, Taniguchi H, Ito Y, et al
    Clinicopathological factors and tumor microenvironment markers predicting watch-and-wait discontinuation in 82 patients with follicular lymphoma.
    Eur J Haematol. 2021 Apr 27. doi: 10.1111/ejh.13637.
    PubMed     Abstract available

    March 2021
  9. OKABE M, Morishita T, Yasuda T, Sakaguchi H, et al
    Targeted deep next generation sequencing identifies potential somatic and germline variants for predisposition to familial Burkitt lymphoma.
    Eur J Haematol. 2021 Mar 27. doi: 10.1111/ejh.13629.
    PubMed     Abstract available

  10. MELODY M, Gandhi S, Rahman ZA, Diaz PL, et al
    Impact of Hypoalbuminemia on the Prognosis of Relapsed/Refractory B-Cell Lymphoma Treated with Axicabtagene Ciloleucel.
    Eur J Haematol. 2021 Mar 2. doi: 10.1111/ejh.13609.
    PubMed     Abstract available

    February 2021
  11. ZDUNIAK A, Mihailescu SD, Lequesne J, Lenain P, et al
    Outcomes after intensive care unit admission in newly diagnosed diffuse large B-cell lymphoma patients: a real-life study.
    Eur J Haematol. 2021 Feb 23. doi: 10.1111/ejh.13606.
    PubMed     Abstract available

  12. VACHON H, Mierzynska J, Taye M, Pe M, et al
    Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin Lymphoma and in Hodgkin Lymphoma survivors.
    Eur J Haematol. 2021 Feb 11. doi: 10.1111/ejh.13601.
    PubMed     Abstract available

    January 2021
  13. ABDAYEM P, Ibrahim N, El Dakdouki Y, Willekens C, et al
    Attenuated Cytarabine, Etoposide, Dexamethasone plus Rituximab (R-Mini-CYVE) Regimen for Patients with Relapsed or Refractory B-cell non-Hodgkin's Lymphoma not Eligible for Intensive Chemotherapy.
    Eur J Haematol. 2021 Jan 29. doi: 10.1111/ejh.13589.
    PubMed     Abstract available

  14. ROCHE P, Venton G, Berda-Haddad Y, Fritz S, et al
    Could Daratumumab induce the maturation of plasmablasts in Plasmablastic Lymphoma? Potential therapeutic applications.
    Eur J Haematol. 2021 Jan 20. doi: 10.1111/ejh.13584.
    PubMed     Abstract available

    December 2020
  15. VAN DE WYNGAERT Z, Coppo P, Cervera P, Fabiani B, et al
    Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide (ICE) in relapsed/refractory peripheral T-cell lymphoma.
    Eur J Haematol. 2020 Dec 15. doi: 10.1111/ejh.13568.
    PubMed     Abstract available

  16. SEKINE M, Kameda T, Shide K, Maeda K, et al
    Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T-cell leukemia/lymphoma.
    Eur J Haematol. 2020 Dec 10. doi: 10.1111/ejh.13565.
    PubMed     Abstract available

    November 2020
  17. PICARDI M, Giordano C, Della Pepa R, Cerchione C, et al
    Correspondence in reference to previously published manuscript: "Faouzi Djebbari et al. Efficacy and infection morbidity of front-line immuno-chemotherapy in follicular lymphoma. Eur J Haematol 2020; 105: 667-671."
    Eur J Haematol. 2020 Nov 30. doi: 10.1111/ejh.13558.
    PubMed     Abstract available

  18. MOZAS P, Sorigue M, Rivas-Delgado A, Rivero A, et al
    The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients.
    Eur J Haematol. 2020 Nov 28. doi: 10.1111/ejh.13556.
    PubMed     Abstract available

  19. SANCHEZ-PINA JM, Rodriguez Rodriguez M, Castro Quismondo N, Gil Manso R, et al
    Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies.
    Eur J Haematol. 2020;105:597-607.
    PubMed     Abstract available

    October 2020
  20. NOZAKI K, Maruyama D, Maeshima AM, Tajima K, et al
    The role of local radiotherapy following rituximab-containing chemotherapy in patients with transformed indolent B-cell lymphoma.
    Eur J Haematol. 2020 Oct 24. doi: 10.1111/ejh.13539.
    PubMed     Abstract available

  21. UCHIDA Y, Yoshimitsu M, Hachiman M, Kusano S, et al
    RLTPR Q575E: A novel recurrent gain-of-function mutation in patients with adult T-cell leukemia/lymphoma.
    Eur J Haematol. 2020 Oct 24. doi: 10.1111/ejh.13540.
    PubMed     Abstract available

  22. BELLMANN-WEILER R, Burkert F, Schwaiger T, Schmidt S, et al
    Janus-faced course of COVID-19 infection in patients with hematological malignancies.
    Eur J Haematol. 2020;105:502-504.

    September 2020
  23. KADDU-MULINDWA D, Rosolowski M, Ziepert M, Regitz E, et al
    VEGFR2 and VEGFA polymorphism are not associated with an inferior prognosis in Caucasian patients with aggressive B-cell lymphoma.
    Eur J Haematol. 2020 Sep 30. doi: 10.1111/ejh.13526.
    PubMed     Abstract available

    August 2020
  24. SANTOPIETRO M, Kovalchuk S, Battistini R, Puccini B, et al
    Treatment and prognosis of primary pulmonary lymphoma: a long-term follow-up study.
    Eur J Haematol. 2020 Aug 11. doi: 10.1111/ejh.13507.
    PubMed     Abstract available

    July 2020
  25. DJEBBARI F, Kaji F, Stanton L, Lawrence MM, et al
    Efficacy and infection morbidity of frontline immuno-chemotherapy in follicular lymphoma.
    Eur J Haematol. 2020 Jul 15. doi: 10.1111/ejh.13486.
    PubMed     Abstract available

  26. POLLARI M, Pellinen T, Karjalainen-Lindsberg ML, Kellokumpu-Lehtinen PL, et al
    Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma.
    Eur J Haematol. 2020 Jul 6. doi: 10.1111/ejh.13484.
    PubMed     Abstract available

    June 2020
  27. SATAKE A, Konishi A, Azuma Y, Tsubokura Y, et al
    Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis.
    Eur J Haematol. 2020 Jun 21. doi: 10.1111/ejh.13474.
    PubMed     Abstract available

  28. FACCHINELLI D, Sina S, Boninsegna E, Borin A, et al
    Primary Pancreatic Lymphoma: Clinical Presentation, Diagnosis, Treatment and Outcome.
    Eur J Haematol. 2020 Jun 16. doi: 10.1111/ejh.13468.
    PubMed     Abstract available

  29. MCILROY G, Barmayehvar B, Kamarajah SK, George L, et al
    Improved outcomes with allogeneic compared with autologous stem cell transplantation in aggressive T-cell lymphoma.
    Eur J Haematol. 2020 Jun 8. doi: 10.1111/ejh.13465.
    PubMed     Abstract available

    May 2020
  30. CHOU WC, Chang H, Wang PN, Kuo MC, et al
    Application of comprehensive geriatric assessment in predicting early mortality among elder patients with B-cell lymphoma receiving immunochemotherapy.
    Eur J Haematol. 2020 May 30. doi: 10.1111/ejh.13457.
    PubMed     Abstract available

  31. SANCHO JM, Navarro B, Soler Campos JA, de Oteyza JP, et al
    Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.
    Eur J Haematol. 2020;104:499-508.
    PubMed     Abstract available

    April 2020
  32. LACOUT C, Orvain C, Seegers V, De Vries M, et al
    R-DHA-oxaliplatin (R-DHAOx) versus R-DHA-cisplatin (R-DHAP) regimen in B-cell lymphoma treatment.
    Eur J Haematol. 2020 Apr 17. doi: 10.1111/ejh.13429.
    PubMed     Abstract available

  33. KARI EJM, Kuusisto MEL, Honkavaara P, Hakalahti A, et al
    Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment.
    Eur J Haematol. 2020 Apr 5. doi: 10.1111/ejh.13419.
    PubMed     Abstract available

    March 2020
  34. WAGNER SM, Melchardt T, Egle A, Magnes T, et al
    Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
    Eur J Haematol. 2020;104:251-258.
    PubMed     Abstract available

    February 2020
  35. IANNITTO E, Romano A, Scalzulli PR, Bonanno V, et al
    Brentuximab vedotin in association with Bendamustine in refractory or multiple relapsed Hodgkin Lymphoma. A retrospective real-world study.
    Eur J Haematol. 2020 Feb 27. doi: 10.1111/ejh.13400.
    PubMed     Abstract available

    January 2020
  36. ZHOU X, Wuchter P, Egerer G, Kriegsmann M, et al
    Serological hepatitis B virus (HBV) activity in patients with HBV infection and B-cell non-Hodgkin's lymphoma.
    Eur J Haematol. 2020 Jan 21. doi: 10.1111/ejh.13388.
    PubMed     Abstract available

  37. XU J, Liu JL, Medeiros LJ, Huang W, et al
    MYC Rearrangement and MYC/BCL2 Double Expression but not Cell-of-Origin Predict Prognosis in R-CHOP-Treated Diffuse Large B Cell Lymphoma.
    Eur J Haematol. 2020 Jan 15. doi: 10.1111/ejh.13384.
    PubMed     Abstract available

  38. ZHOU X, Steinhardt MJ, Dull J, Krummenast F, et al
    Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma.
    Eur J Haematol. 2020 Jan 10. doi: 10.1111/ejh.13382.
    PubMed     Abstract available

    December 2019
  39. MICHOT JM, Annereau M, Danu A, Legoupil C, et al
    High-Dose Cyclophosphamide for hard-to-treat patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, a phase II result.
    Eur J Haematol. 2019 Dec 14. doi: 10.1111/ejh.13369.
    PubMed     Abstract available

  40. GUTIERREZ A, Bento L, Diaz-Lopez A, Barranco G, et al
    Evaluation of The MD Anderson Tumor Score for Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Eur J Haematol. 2019 Dec 5. doi: 10.1111/ejh.13364.
    PubMed     Abstract available

  41. KAWAJIRI A, Kitano S, Maeshima AM, Inamoto Y, et al
    Association of CD204(+) macrophages with poor outcomes of malignant lymphomas not in remission treated by allogeneic HCT.
    Eur J Haematol. 2019;103:578-587.
    PubMed     Abstract available

    November 2019
  42. ABDULLA M, Guglielmo P, Hollander P, Astrom G, et al
    Prognostic impact of abdominal lymph node involvement in diffuse large B-cell lymphoma.
    Eur J Haematol. 2019 Nov 30. doi: 10.1111/ejh.13361.
    PubMed     Abstract available

  43. MERCADAL S, Sancho JM, Climent F, Tapia G, et al
    Long-term Outcome comparing Histological Grades of Follicular Lymphoma Patients Treated with Immunochemotherapy as First Line Therapy. A Retrospective Analysis from Two Institutions".
    Eur J Haematol. 2019 Nov 26. doi: 10.1111/ejh.13359.
    PubMed     Abstract available

  44. TANEJA A, Kumar V, Chandra AB
    Primary Renal Lymphoma: A Population-based Analysis Using the SEER Program (1973-2015).
    Eur J Haematol. 2019 Nov 26. doi: 10.1111/ejh.13360.
    PubMed     Abstract available

    October 2019
  45. MALENDA A, Kolkowska-Lesniak A, Pula B, Dlugosz-Danecka M, et al
    Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma.
    Eur J Haematol. 2019 Oct 13. doi: 10.1111/ejh.13337.
    PubMed     Abstract available

    September 2019
  46. ATALLAH-YUNES SA, Murphy D, Abdelmalak R, Mantle L, et al
    Plasmablastic lymphoma achieving sustained remission with antiretroviral therapy alone.
    Eur J Haematol. 2019 Sep 10. doi: 10.1111/ejh.13326.
    PubMed     Abstract available

    August 2019
  47. SINDEL A, Taylor T, Chesney A, Clark W, et al
    Hematopoietic stem cell mobilization following PD-1 blockade: Cytokine release syndrome after transplantation managed with ascorbic acid.
    Eur J Haematol. 2019;103:134-136.
    PubMed     Abstract available

    July 2019
  48. ZHOU X, Wuchter P, Egerer G, Kriegsmann M, et al
    Role of Virological Serum Markers in patients with both Hepatitis B virus infection and Diffuse Large B-cell Lymphoma.
    Eur J Haematol. 2019 Jul 23. doi: 10.1111/ejh.13300.
    PubMed     Abstract available

  49. KNAUF W, Abenhardt W, Mohm J, Rauh J, et al
    Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma - Data from the prospective German Tumour Registry Lymphatic Neoplasms.
    Eur J Haematol. 2019 Jul 17. doi: 10.1111/ejh.13295.
    PubMed     Abstract available

    June 2019
  50. KEANE C, Tobin J, Gunawardana J, Francis S, et al
    The tumor microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV positive Diffuse Large B Cell Lymphoma.
    Eur J Haematol. 2019 Jun 18. doi: 10.1111/ejh.13274.
    PubMed     Abstract available

  51. WANG L, Peng S, Sun W, Liu X, et al
    Bevacizumab synergizes with the BCL 2 inhibitor venetoclax to effectively treat B-cell non-Hodgkin's lymphoma.
    Eur J Haematol. 2019 Jun 18. doi: 10.1111/ejh.13279.
    PubMed     Abstract available

  52. HEGER JM, Eichenauer DA, Kasper P, Boll B, et al
    Fatal disseminated enterovirus infection in a patient with follicular lymphoma undergoing obinutuzumab maintenance therapy.
    Eur J Haematol. 2019 Jun 18. doi: 10.1111/ejh.13278.
    PubMed     Abstract available

  53. DADA R
    Diagnosis and management of follicular lymphoma: A comprehensive review.
    Eur J Haematol. 2019 Jun 10. doi: 10.1111/ejh.13271.
    PubMed     Abstract available

  54. MILUNOVIC V, Misura Jakobac K, Kursar M, Mandac Rogulj I, et al
    FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: another player in the town?
    Eur J Haematol. 2019 Jun 5. doi: 10.1111/ejh.13269.
    PubMed     Abstract available

    April 2019
  55. CRICKX E, Poullot E, Moulis G, Goulabchand R, et al
    Clinical spectrum, evolution and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma.
    Eur J Haematol. 2019 Apr 15. doi: 10.1111/ejh.13239.
    PubMed     Abstract available

  56. FERRARO MP, Gimeno-Vazquez E, Subirana I, Gomez M, et al
    Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification.
    Eur J Haematol. 2019 Apr 10. doi: 10.1111/ejh.13234.
    PubMed     Abstract available

    March 2019
  57. VAHAMURTO P, Mannisto S, Pollari M, Karjalainen-Lindsberg ML, et al
    Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre and rituximab eras.
    Eur J Haematol. 2019 Mar 4. doi: 10.1111/ejh.13225.
    PubMed     Abstract available

    February 2019
  58. ISHITSUKA K, Yurimoto S, Tsuji Y, Iwabuchi M, et al
    Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma.
    Eur J Haematol. 2019 Feb 10. doi: 10.1111/ejh.13220.
    PubMed     Abstract available

  59. PEDERSEN MO, Gang AO, Linde EC, Breinholt MF, et al
    Stratification by MYC expression has prognostic impact in MYC/BCL2 translocated B-cell lymphoma - identifies a subgroup of patients with poor outcome.
    Eur J Haematol. 2019 Feb 9. doi: 10.1111/ejh.13219.
    PubMed     Abstract available

    November 2018
  60. SAKAROU M, Eisele L, Duhrsen U, Huttmann A, et al
    Efficacy of the GMALL-B-ALL/NHL2002 Protocol in Burkitt Leukaemia/Lymphoma and Aggressive Non-Hodgkin-Lymphomas with or without CNS-Involvement.
    Eur J Haematol. 2018 Nov 24. doi: 10.1111/ejh.13199.
    PubMed     Abstract available

  61. YONESE I, Takase H, Yoshimori M, Onozawa E, et al
    CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential.
    Eur J Haematol. 2018 Nov 2. doi: 10.1111/ejh.13191.
    PubMed     Abstract available

    October 2018
  62. WOLFF T, Schulz H, Losem C, Reichert D, et al
    Prophylaxis of Chemotherapy-induced Neutropenia and Febrile Neutropenia with Lipegfilgrastim in Patients with Non-Hodgkin Lymphoma (NADIR study).
    Eur J Haematol. 2018 Oct 22. doi: 10.1111/ejh.13189.
    PubMed     Abstract available

  63. DADA R, Usman B
    Allogeneic hematopoietic stem cell transplantation in r/r Hodgkin lymphoma after treatment with checkpoint-inhibitors: feasibility and safety.
    Eur J Haematol. 2018 Oct 20. doi: 10.1111/ejh.13186.
    PubMed     Abstract available

    July 2018
  64. KRIEGSMANN K, Wack M, Kriegsmann M, Cremer M, et al
    Selective Contrast-enhanced Computed Tomography is Appropriate in Diffuse Large B-cell Lymphoma Therapy Response Assessment.
    Eur J Haematol. 2018 Jul 26. doi: 10.1111/ejh.13150.
    PubMed     Abstract available

  65. REPETTO-LLAMAZARES AHV, Malenge MM, O'Shea A, Eiriksdottir B, et al
    Combination of (177) Lu-lilotomab with rituximab significantly improves the therapeutic outcome in pre-clinical models of non-Hodgkin's lymphoma.
    Eur J Haematol. 2018 Jul 11. doi: 10.1111/ejh.13139.
    PubMed     Abstract available

  66. SPUKTI EU, Schmidt LH, Schulze A, Schliemann C, et al
    (90) Y-ibritumomab-tiuxetan as a therapeutic alternative for Follicular lymphoma (FL): A single-center experience.
    Eur J Haematol. 2018 Jul 11. doi: 10.1111/ejh.13138.
    PubMed     Abstract available

    June 2018
  67. SU YJ, Wang PN, Chang H, Shih LY, et al
    Extranodal NK/T Cell Lymphoma, Nasal Type: Clinical Features, Outcome and Prognostic Factors in 101 Cases.
    Eur J Haematol. 2018 Jun 16. doi: 10.1111/ejh.13126.
    PubMed     Abstract available

  68. ZHOU LL, Xu XY, Ni J, Zhao X, et al
    T-cell lymphomas associated gene expression signature: Bioinformatics analysis based on gene expression Omnibus.
    Eur J Haematol. 2018;100:575-583.
    PubMed     Abstract available

    May 2018
  69. NOESSLINGER T, Panny M, Simanek R, Moestl M, et al
    High dose Bendamustine-EAM followed by autologous stem cell rescue results in long term remission rates in lymphoma patients, without renal toxicty.
    Eur J Haematol. 2018 May 25. doi: 10.1111/ejh.13102.
    PubMed     Abstract available

  70. SORIGUE M, Tuset V, Sancho JM
    Treatment of localized-stage follicular lymphoma.
    Eur J Haematol. 2018 May 12. doi: 10.1111/ejh.13093.
    PubMed     Abstract available

  71. BJORKHOLM M, Weibull CE, Eloranta S, Smedby KE, et al
    Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma - a population-based study from Sweden.
    Eur J Haematol. 2018 May 4. doi: 10.1111/ejh.13090.
    PubMed     Abstract available

  72. GOLSTEIN S, Muylle K, Vercruyssen M, Spilleboudt C, et al
    Long-term follow-up of 2 patients treated with (90) Y-rituximab Radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphoma.
    Eur J Haematol. 2018 May 2. doi: 10.1111/ejh.13087.
    PubMed     Abstract available

    April 2018
  73. MEISTER A, Hentrich M, Wyen C, Hubel K, et al
    Malignant lymphoma in the HIV-positive patient.
    Eur J Haematol. 2018 Apr 16. doi: 10.1111/ejh.13082.
    PubMed     Abstract available

  74. GRIGNANO E, Laurent J, Deau B, Burroni B, et al
    The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and high risk diffuse large B-cell lymphoma.
    Eur J Haematol. 2018 Apr 16. doi: 10.1111/ejh.13080.
    PubMed     Abstract available

  75. TERZIEV D, Hutter B, Klink B, Stenzinger A, et al
    Nivolumab maintenance after salvage autologous stem cell transplantation results in long term remission in multiple relapsed primary cns lymphoma.
    Eur J Haematol. 2018 Apr 6. doi: 10.1111/ejh.13072.
    PubMed     Abstract available

    March 2018
  76. CHENG CL, Liu JH, Chou SC, Yao M, et al
    Retrospective analysis of front line treatment efficacy in elderly patients with diffuse large B-cell lymphoma.
    Eur J Haematol. 2018 Mar 30. doi: 10.1111/ejh.13069.
    PubMed     Abstract available

  77. KRIEGSMANN K, Rieger M, Schwarzbich MA, Sitter S, et al
    Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma.
    Eur J Haematol. 2018 Mar 25. doi: 10.1111/ejh.13064.
    PubMed     Abstract available

  78. LAKSHMAIAH KC, Asati V, Babu KG, Lokanath D, et al
    Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma.
    Eur J Haematol. 2018 Mar 22. doi: 10.1111/ejh.13068.
    PubMed     Abstract available

  79. GASCON P, Krendyukov A, Hobel N, Aapro M, et al
    MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.
    Eur J Haematol. 2018;100:241-246.
    PubMed     Abstract available

    February 2018
  80. BOUTSIKAS G, Terpos E, Papatheodorou A, Tsirkinidis P, et al
    Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy/autologous hematopoietic stem cell transplantation.
    Eur J Haematol. 2018;100:131-139.
    PubMed     Abstract available

    January 2018
  81. TANAKA Y, Maeshima AM, Nomoto J, Makita S, et al
    Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
    Eur J Haematol. 2018 Jan 28. doi: 10.1111/ejh.13033.
    PubMed     Abstract available

    December 2017
  82. JAMROZIAK K, Szymczyk A, Hus M, Wojciechowska M, et al
    Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG).
    Eur J Haematol. 2017 Dec 15. doi: 10.1111/ejh.13016.
    PubMed     Abstract available

    November 2017
  83. LI JW, Li YJ, Zhong MZ, Liu XL, et al
    Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-Cell lymphoma: A multicenter retrospective study.
    Eur J Haematol. 2017 Nov 30. doi: 10.1111/ejh.13004.
    PubMed     Abstract available

  84. SCHILLER J, Klein S, Engels M, Buttner R, et al
    A Cryptosporidium infection in a patient with relapsed T lymphoblastic lymphoma undergoing allogeneic stem cell transplantation.
    Eur J Haematol. 2017 Nov 15. doi: 10.1111/ejh.12998.
    PubMed     Abstract available

    October 2017
  85. HOLLANDER P, Rostgaard K, Smedby KE, Molin D, et al
    An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome.
    Eur J Haematol. 2017 Oct 24. doi: 10.1111/ejh.12987.
    PubMed     Abstract available

  86. ELORANTA S, Branvall E, Celsing F, Papworth K, et al
    Increasing incidence of Primary CNS lymphoma but no improvement in survival in Sweden 2000-2013.
    Eur J Haematol. 2017 Oct 6. doi: 10.1111/ejh.12980.
    PubMed     Abstract available

    September 2017
  87. BROCKELMANN PJ, Zagadailov EA, Corman SL, Chirikov V, et al
    Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma who are Ineligible for Autologous Stem Cell Transplant: A Germany and UK Retrospective Study.
    Eur J Haematol. 2017 Sep 26. doi: 10.1111/ejh.12973.
    PubMed     Abstract available

    June 2017
  88. CAMPIONI D, Gentili V, Cavazzini F, Bortolotti D, et al
    Detection of inherited chromosomally integrated HHV-6 (ciHHV-6) in a marker chromosome.
    Eur J Haematol. 2017;98:635-637.
    PubMed     Abstract available

    May 2017
  89. GLAVEY S, Quinn J, McCloy M, Sargent J, et al
    Emergence of Bruton's Tyrosine Kinase-negative Hodgkin Lymphoma During Ibrutinib Treatment of Chronic Lymphocytic Leukaemia.
    Eur J Haematol. 2017 May 31. doi: 10.1111/ejh.12911.
    PubMed     Abstract available

  90. KAWAMOTO K, Miyoshi H, Yanagida E, Yoshida N, et al
    Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
    Eur J Haematol. 2017;98:459-466.
    PubMed     Abstract available

    February 2017
  91. THOTA S, Advani A
    Inotuzumab ozogamicin in relapsed b-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2017 Feb 2. doi: 10.1111/ejh.12862.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.